Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer.
aspirin
cohort study
colorectal cancer
diagnosis
metastasis
mortality
pharmacoepidemiology
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
29
11
2019
revised:
20
04
2020
accepted:
21
04
2020
pubmed:
1
5
2020
medline:
29
7
2021
entrez:
1
5
2020
Statut:
ppublish
Résumé
Previous studies suggest that the use of low-dose aspirin before a colorectal cancer (CRC) diagnosis may be associated with a decreased risk of CRC progression. Data supporting this association, however, have been inconsistent. We evaluate whether the use of prediagnostic low-dose aspirin is associated with a lower risk of metastases and all-cause mortality in CRC patients. Using a large Italian population-based primary care database, we identified a cohort of 7478 patients newly diagnosed with nonmetastatic CRC between 2000 and 2013. Use of prediagnostic low-dose aspirin was compared with no use of low-dose aspirin. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of incident metastasis and of all-cause mortality associated with prediagnostic low-dose aspirin use, both overall and by duration of use. There were 314 incident metastatic events and 2189 deaths during a mean follow-up time of 4.4 and 4.7 years, respectively. Overall prediagnostic use of low-dose aspirin was not associated with a decreased risk of incident metastasis (HR 0.88; 95% CI 0.63-1.22) or all-cause mortality (HR 1.09; 95% CI 0.96-1.22) in CRC patients. Cumulative duration of aspirin use was not associated with a decreased risk of incident metastasis (P-trend = .22) or all-cause mortality (P-trend = .38). These findings remained consistent in sensitivity analyses. In this real-world, population-based study, the prediagnostic use of low-dose aspirin was not associated with a decreased risk of incident metastasis or all-cause mortality in CRC patients.
Identifiants
pubmed: 32352592
doi: 10.1111/bcp.14329
pmc: PMC7576616
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2266-2273Subventions
Organisme : CIHR
ID : FN‐152254
Pays : Canada
Informations de copyright
© 2020 The British Pharmacological Society.
Références
Am J Epidemiol. 2008 Feb 15;167(4):492-9
pubmed: 18056625
Int J Clin Exp Med. 2015 Aug 15;8(8):13435-45
pubmed: 26550280
Lancet Oncol. 2012 May;13(5):518-27
pubmed: 22440112
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):1966-73
pubmed: 22933426
J Public Health Med. 2003 Sep;25(3):254-7
pubmed: 14575204
Cancer. 2009 Dec 15;115(24):5662-71
pubmed: 19827153
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMJ. 1997 Nov 1;315(7116):1151-4
pubmed: 9374894
J Public Health Med. 1999 Sep;21(3):299-304
pubmed: 10528957
Gut. 2010 Dec;59(12):1670-9
pubmed: 20844293
Br J Clin Pharmacol. 2020 Nov;86(11):2266-2273
pubmed: 32352592
Gut. 2011 Apr;60(4):491-8
pubmed: 21051449
Stat Methods Med Res. 2009 Feb;18(1):67-80
pubmed: 18562398
BMC Cancer. 2018 Feb 27;18(1):228
pubmed: 29486728
Ann Intern Med. 2016 Jun 21;164(12):836-45
pubmed: 27064677
BMJ Open. 2018 Jul 5;8(7):e020630
pubmed: 29980543
Br J Cancer. 2012 Oct 23;107(9):1602-7
pubmed: 23011483